RxDoctor Payments Data

Erol Ulker, MD

Urology · Belleville, NJNPI 1083633283

Payments from drug & device makers

$803in general payments, 2019–2025

Across 38 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$215
  • Medtronic$135
  • Koelis Inc.$99
  • Bayer$85
  • AbbVie$72
  • Pfizer$57
  • plus $141 from 4 others

What the payments were for

  • Food & beverage$803100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc12$215
Medtronic(2 entities)2$135
Koelis Inc.1$99
Bayer4$85
AbbVie(2 entities)5$72
Pfizer4$57
Endo Pharmaceuticals Inc.4$49
Amgen3$41
Boston Scientific2$35
Johnson & Johnson1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$803 in reported general payments places this provider in the 25th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$194,663
Medicare patients
413
Services billed
3,818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron72$33,207
GemtesaVibegron38$22,856
ElmironPentosan Polysulfate Sodium13$18,899
PremarinEstrogens, Conjugated23$10,129
Tamsulosin Hcl524$6,970
Solifenacin Succinate96$5,641
Dutasteride98$4,533
Oxybutynin Chloride ErOxybutynin Chloride204$3,436
Tolterodine Tartrate ErTolterodine Tartrate44$1,825
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst30$606
Finasteride39$548
Imipramine Hcl19$402
Oxybutynin Chloride26$370
Ciprofloxacin Hcl32$306
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav29$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$215$33,20772 claims
PfizerPremarin$57$10,12923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 401 urology providers in New Jersey.

Other urology in Belleville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →